• Je něco špatně v tomto záznamu ?

Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial

PJ. Raubenheimer, WC. Cushman, A. Avezum, J. Basile, I. Conget, G. Dagenais, A. Hoover, P. Jansky, F. Lanas, LA. Leiter, P. Lopez-Jaramillo, N. Pogosova, J. Probstfield, P. Rao-Melacini, L. Rydén, WH. Sheu, T. Temelkova-Kurktschiev, H. C Gerstein

. 2022 ; 24 (4) : 704-712. [pub] 20220124

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018932

AIM: To assess the occurrence of atrial fibrillation or atrial flutter (atrial arrhythmias [AA]) in patients with type 2 diabetes treated with once-weekly subcutaneous dulaglutide versus placebo. MATERIALS AND METHODS: Patients without electrocardiographic (ECG)-confirmed AA at baseline and randomized in the REWIND trial were assessed for the development of AA based on an annual ECG. Additional analyses included whether dulaglutide compared with placebo reduced the composite outcome of AA or death, AA or cardiovascular death, AA or stroke and AA or heart failure. RESULTS: Among 9543 participants (mean age 66 ± 7 years, with cardiovascular risk factors and 31% with previous cardiovascular disease) without AA at entry in the trial, 524 patients (5.5%) had at least one episode of AA during the median 5.4 years of follow-up. Incident AA occurred in 269 of the 4769 participants allocated to dulaglutide (5.6%), at a rate of 10.7 per 1000 person-years, versus 255 of the 4774 allocated to placebo (5.3%), at a rate of 10.5 per 1000 person-years (P = .59). There was also no effect of dulaglutide on the composite outcome of AA and death or AA and heart failure. CONCLUSION: This post hoc analysis of data from the REWIND trial showed that treatment with dulaglutide was not associated with a reduced incidence of AA in this at-risk group of patients with type 2 diabetes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018932
003      
CZ-PrNML
005      
20220804135210.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/dom.14634 $2 doi
035    __
$a (PubMed)34984808
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Raubenheimer, Peter J $u Division of Endocrinology, Department of Medicine, University of Cape Town, Cape Town, South Africa $1 https://orcid.org/0000000254161286
245    10
$a Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial / $c PJ. Raubenheimer, WC. Cushman, A. Avezum, J. Basile, I. Conget, G. Dagenais, A. Hoover, P. Jansky, F. Lanas, LA. Leiter, P. Lopez-Jaramillo, N. Pogosova, J. Probstfield, P. Rao-Melacini, L. Rydén, WH. Sheu, T. Temelkova-Kurktschiev, H. C Gerstein
520    9_
$a AIM: To assess the occurrence of atrial fibrillation or atrial flutter (atrial arrhythmias [AA]) in patients with type 2 diabetes treated with once-weekly subcutaneous dulaglutide versus placebo. MATERIALS AND METHODS: Patients without electrocardiographic (ECG)-confirmed AA at baseline and randomized in the REWIND trial were assessed for the development of AA based on an annual ECG. Additional analyses included whether dulaglutide compared with placebo reduced the composite outcome of AA or death, AA or cardiovascular death, AA or stroke and AA or heart failure. RESULTS: Among 9543 participants (mean age 66 ± 7 years, with cardiovascular risk factors and 31% with previous cardiovascular disease) without AA at entry in the trial, 524 patients (5.5%) had at least one episode of AA during the median 5.4 years of follow-up. Incident AA occurred in 269 of the 4769 participants allocated to dulaglutide (5.6%), at a rate of 10.7 per 1000 person-years, versus 255 of the 4774 allocated to placebo (5.3%), at a rate of 10.5 per 1000 person-years (P = .59). There was also no effect of dulaglutide on the composite outcome of AA and death or AA and heart failure. CONCLUSION: This post hoc analysis of data from the REWIND trial showed that treatment with dulaglutide was not associated with a reduced incidence of AA in this at-risk group of patients with type 2 diabetes.
650    _2
$a senioři $7 D000368
650    12
$a fibrilace síní $x komplikace $x farmakoterapie $x epidemiologie $7 D001281
650    12
$a diabetes mellitus 2. typu $x komplikace $x farmakoterapie $x epidemiologie $7 D003924
650    _2
$a glukagonu podobné peptidy $x analogy a deriváty $7 D004763
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemika $7 D007004
650    _2
$a imunoglobuliny - Fc fragmenty $x škodlivé účinky $7 D007141
650    _2
$a lidé středního věku $7 D008875
650    _2
$a rekombinantní fúzní proteiny $x škodlivé účinky $7 D011993
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cushman, William C $u University of Tennessee Health Science Center, Memphis, Tennessee, USA
700    1_
$a Avezum, Alvaro $u International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil
700    1_
$a Basile, Jan $u Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina, USA
700    1_
$a Conget, Ignacio $u Endocrinology and Nutrition Department, Hospital Clínic, University of Barcelona, Barcelona, Spain $1 https://orcid.org/0000000255325449
700    1_
$a Dagenais, Gilles $u Institut Universitaire de Cardiologie et de Pneumologie de Québec. Université Laval Institute, Quebec City, Quebec, Canada $1 https://orcid.org/0000000245092004
700    1_
$a Hoover, Anastasia $u Eli Lilly and Company, Indianapolis, Indiana, USA
700    1_
$a Jansky, Petr $u University Hospital Motol, Prague, Czech Republic
700    1_
$a Lanas, Fernando $u Universidad de La Fontera, Temuco, Chile
700    1_
$a Leiter, Lawrence A $u Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
700    1_
$a Lopez-Jaramillo, Patricio $u Masira Research Institute, Medical School, Universidad de Santander (UDES), Bucaramanga, Colombia
700    1_
$a Pogosova, Nana $u National Medical Research Center of Cardiology, Moscow, Russia
700    1_
$a Probstfield, Jeffrey $u Department of Medicine, University of Washington, Seattle, Washington, USA
700    1_
$a Rao-Melacini, Purnima $u Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
700    1_
$a Rydén, Lars $u Department of Medicine, Karolinska Institut, Stockholm, Sweden
700    1_
$a Sheu, Wayne H-H $u Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
700    1_
$a Temelkova-Kurktschiev, Theodora $u Robert Koch Medical Centre, Sofia, Bulgaria
700    1_
$a C Gerstein, Hertzel $u Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada $1 https://orcid.org/0000000180722836
773    0_
$w MED00005425 $t Diabetes, obesity & metabolism $x 1463-1326 $g Roč. 24, č. 4 (2022), s. 704-712
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34984808 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135203 $b ABA008
999    __
$a ok $b bmc $g 1822500 $s 1170175
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 24 $c 4 $d 704-712 $e 20220124 $i 1463-1326 $m Diabetes, obesity and metabolism $n Diabetes Obes Metab $x MED00005425
LZP    __
$a Pubmed-20220720
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace